D. E. Shaw & Co., Inc. 89bio, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $98.6 Billion
- Q2 2024
Call Options
1 transactions
Others Institutions Holding ETNB
# of Institutions
157Shares Held
107MCall Options Held
65KPut Options Held
1.2M-
Ra Capital Management, L.P. Boston, MA14.2MShares$102 Million1.71% of portfolio
-
Janus Henderson Group PLC London, X013.3MShares$95.5 Million0.06% of portfolio
-
Suvretta Capital Management, LLC New York, NY8.03MShares$57.7 Million2.69% of portfolio
-
Bvf Inc San Francisco, CA7.57MShares$54.4 Million1.85% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$53.1 Million0.99% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $334M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...